

Institut für Reproduktionstoxikologie Medikamentenberatung in Schwangerschaft und Stillzeit

Institut für Reproduktionstoxikologie Postfach 2790 88191 Ravensburg

Klinikum Ingolstadt / Frauenklinik
Frau Dr.
Krumenauerstr. 25


85049 Ingolstadt



St. Elisabeth-Stiftung

Leitung: Dr. med. W. Paulus

Sitz am
Krankenhaus St. Elisabeth der

 **Oberschwaben** ^{Klinik}
Akademisches Lehrkrankenhaus
der Universität Ulm

20.11.2007

Ihre Anfrage vom 20.11.2007

Sehr geehrte Frau Kollegin,

in Ihrer Anfrage vom 20.11.2007 wünschten Sie Informationen über die Auswirkungen einer Einnahme von **Zofran** in der Schwangerschaft bei Ihrer Patientin

Unter den Serotoninantagonisten wie Ondansetron (Zofran®), Dolasetron oder Tropisetron liegen in der menschlichen Schwangerschaft lediglich für Ondansetron einige Erfahrungen vor.

Ondansetron zeigte in reproduktionstoxikologischen Studien an Ratten und Kaninchen in Dosen bis 4 mg/kg/d keine teratogenen Effekte (Product information Zofran 1997).

Berichte über den erfolgreichen Einsatz von Ondansetron bei therapierefraktärem Erbrechen in der Schwangerschaft liegen vor (Guikotes et al 1992; World 1993; Sullivan et al 1995, 1996; Tincello & Johnstone 1996): Bei 17 publizierten Fällen zeigten sich überwiegend deutliche Verbesserungen der Symptomatik ohne fetale Schäden trotz meist längerfristiger Anwendung. Eine neuere Studie berichtet von 176 Schwangerschaften unter Medikation mit Ondansetron im ersten Schwangerschaftsdrittel (Einarson et al 2004)

2 Schwangerschaftsabbrüche

5 Spontanaborte

163 unauffällige Neugeborene

6 angeborene Anomalien (3 x Hypospadie, 1 Nierenfehlbildung,
1 x Pulmonalstenose, 1 x Duodenalatresie)

Wir verfügen über 3 Rückmeldungen mit unauffälligen Neugeborenen nach mütterlicher Medikation mit Ondansetron in der Frühschwangerschaft.

Telefon
0751-87 2798

Telefax
0751-87 2798

E-Mail
paulus@reprotox.de

Internet
www.reprotox.de

Anschrift
Elisabethenstraße 17
88212 Ravensburg

Bankverbindung
Kreissparkasse Ravensburg
BLZ 650 501 10
Konto 62 461 364

Die Konzentrationen des Wirkstoffes erreichen im fetalen Gewebe zwischen 41 und 52% der mütterlichen Werte (Siu et al 2006).

Bei therapierefraktärer Hyperemesis Ihrer Patientin wäre die Anwendung von Ondansetron durchaus diskutabel, zumal sie sich bereits am Ende der sensiblen Phase der Organogenese befindet.

Mit freundlichen kollegialen Grüßen



Dr. med. Wolfgang E. Paulus
Institutsleiter

Literatur:

1. Einarson A, Maltepe C, Navioz Y, Kennedy D, Tan MP, Koren G. The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study. *BJOG*. 2004 Sep;111(9):940-3
2. Guikontes E, Spantideas A, Diakakis J. Ondansetron and hyperemesis gravidarum. *Lancet* 1992;340:1223.
3. Product information Zofran. Glaxo Wellcome, 1997.
4. Siu SS, Chan MT, Lau TK. Placental Transfer of Ondansetron during Early Human Pregnancy. *Clin Pharmacokinet*. 2006;45(4):419-23.
5. Sullivan CA, Johnson CA, Roach H, Martin RW, Stewart DK, Morrison JC. A prospective, randomized, double-blind comparison of the serotonin antagonist ondansetron to a standardized regimen of promethazine for hyperemesis gravidarum. A preliminary investigation (abstract). *Am J Obstet Gynecol* 1995;172:299.
6. Sullivan CA, Johnson CA, Roach H, Martin RW, Stewart DK, Morrison JC. A pilot study of intravenous ondansetron for hyperemesis gravidarum. *Am J Obstet Gynecol* 1996;174:1565-8.
7. Tincello DG, Johnstone MJ. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). *Postgrad Med J* 1996;72:688-9.
8. World MJ. Ondansetron and hyperemesis gravidarum. *Lancet* 1993;341:185

Weitere Informationen zu unserem Beratungszentrum finden Sie auf unserer Homepage unter <http://www.reprotox.de> !



Institut für Reproduktionstoxikologie Medikamentenberatung in Schwangerschaft und Stillzeit

Oberschwabenklinik, KH St. Elisabeth, Elisabethenstr. 17, 88212 Ravensburg

Akademisches Lehrkrankenhaus der Universität Ulm

Leitung: Dr. med. W. Paulus

Fax: 0751 8727-98



St. Elisabeth-Stiftung

Formular für neue Anfragen

Code-Nr.: _____ / _____

Datum: _____

Fragesteller/in (Stempel)

Name:

Klinik:

Straße:

PLZ, Wohnort:

Status: Arzt / Ärztin für:

Patientin

Benachrichtigung:

Tel.:

Fax:

E-Mail:

zu erreichen

von _____ bis _____ (Uhrzeit)

Patientin

Name (evtl. Nr.):

geb.:

Anzahl früherer Schwangerschaften:

Geburten:

Fehlgeburten:

Letzte Regel:

Zyklus regelmäßig?

_____ (Tage)

Schwangerschaftsalter nach Ultraschall:

entspricht Schwangerschaftswoche _____ (vollendete Wochen) + _____ (Tage)

Schwangerschaft erwünscht: ja nein indifferent unbekannt

errechneter Entbindungstermin:

Patientin stillt

Krankengeschichte (Erbkrankheiten, Fehlbildungen, chronische Erkrankungen bei Patientin / Familie):

Medikamente

Handelsname/Wirkstoff	Anwendung von bis (Datum!)	Tagesdosis	Grund der Anwendung

Fragestellung:

BJOG: an International Journal of Obstetrics and Gynaecology
September 2004, Vol. 111, pp. 940–943

DOI: 10.1111/j.1471-0528.2004.00236.x

The safety of ondansetron for nausea and vomiting of pregnancy: a prospective comparative study

Adrienne Einarson,^a Caroline Maltepe,^a Yvette Navioz,^a Deborah Kennedy,^b
Michael Paul Tan,^a Gideon Koren^a

Objective Ondansetron (Zofran) is a drug used for the treatment of nausea and vomiting caused by cancer chemotherapy. Despite the fact that it is not indicated, women are being prescribed this drug for the treatment of nausea and vomiting of pregnancy (NVP). There is a paucity of information on fetal safety for this indication. The objective of this study is to determine whether this drug increases the baseline rate of major malformations.

Design A prospective comparative observational study.

Setting Teratogen Information Services (TIS).

Population Pregnant women.

Methods Our three groups included women who were exposed to ondansetron and women exposed to (1) other anti-emetics and (2) non-teratogen exposures. All of the women called either our NVP Helpline or TIS at The Motherisk Program in Toronto, Canada, or The Mothersafe Program in Sydney, Australia.

Main outcome measure Rates of major malformation.

Results We have completed 176 pregnancy outcomes in each group. In the ondansetron cohort, there were 169 live births, 5 miscarriages, 2 therapeutic abortions, 6 (3.6%) major malformations and the mean birthweight was 3362 g [SD 525]. There were no statistical differences in any of the study endpoints between the ondansetron and the comparison groups.

Conclusions This drug does not appear (although the sample size is limited) to be associated with an increased risk for major malformations above baseline.

INTRODUCTION

Nausea and vomiting (NVP) is the most common medical condition of pregnancy, affecting up to 80% of all pregnancies to some degree. In most cases, it resolves by the 16th week of pregnancy, although up to 20% of women continue to have symptoms throughout pregnancy. Severe NVP (hyperemesis gravidarum) affects less than 1% of women but can be debilitating, in the worst case scenario, requiring hospitalisation and rehydration of fluids.¹ Even less severe cases can have a significant impact on the quality of a woman's life, affecting her occupational, social, domestic functioning and general wellbeing.² Although NVP affects such a significant number of pregnant women, it is largely ignored in terms of medical research and in the development of new treatment modalities.

The drug of choice for treatment in Canada is Diclectin, the controlled release of doxylamine + vitamin B6³; however, in the United States, there is no drug approved by the FDA, since the removal of Bendectin 20 years ago due to unfounded fears that it was teratogenic.⁴ Other modes of treatments have been used throughout the world, which include various antihistamines, phenothiazines, vitamin B6, metoclopramide and ginger with various levels of evidence of safety and efficacy.^{5–9}

Despite the fact that ondansetron is not indicated for NVP and there are no studies examining safety in pregnancy, it has been used as a last resort and appears to be effective when no other treatments work. Recently, it was brought to our attention by American callers using our service that it has been used as a first line of treatment in the United States, with HMOs covering the cost.

A program of pre-clinical safety evaluation was undertaken, which involved a series of studies: single dose, repeat dose, reproduction, genotoxicity, oncogenicity, local irritancy and a hypersensitivity study. Ondansetron was found to have a very good safety profile and the only toxicity identified was associated with central nervous system activity when near lethal doses were administered. It was not genotoxic and had no reproductive or oncogenic potential.¹⁰ The efficacy was also studied and it was found to be effective for the prevention of nausea and vomiting

^aThe Motherisk Program, The Hospital for Sick Children, The University of Toronto, Canada

^bMotherSafe Program, Royal Hospital for Women and University of New South Wales, Randwick, Australia

Correspondence: Ms A. Einarson, The Motherisk Program, Division of Clinical Pharmacology, The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, Canada M5G 1X8.

post-chemotherapy.¹¹ However, it was never intended or labeled as such to be a treatment for NVP. Consequently, there is a paucity of data in the literature on the safety of ondansetron for the treatment of NVP: there are three case reports¹² and one small study comprised of 15 subjects with severe NVP (hyperemesis gravidarum) who were compared with women taking promethazine.¹³

At The Motherisk Program, we established a Nausea and Vomiting Help Line in 1996, which is a toll-free line where women from all over North America can call for information about NVP. In an attempt to improve the quality of life of these women, we are continuing to investigate optimal treatment modalities. Several years ago, we found that a significant number of women calling our Helpline, many of whom were calling from the United States, had been prescribed ondansetron and were requesting information on the safety and effectiveness of this drug for NVP. We felt that if ondansetron is to be considered a useful drug for the treatment of NVP, the safety of this drug on the developing fetus must be examined first.

Our objective was to determine whether the use of ondansetron during pregnancy is associated with an increased risk for major malformations.

METHODS

Motherisk and Mothersafe are counselling services for pregnant and lactating women and their health professionals, where information is given on the safety/risk of drugs, chemicals, radiation and infectious diseases. Women who called either service, were taking ondansetron and were less than three months pregnant at the time of call (most were between 5 and 9 weeks of gestation) within a two year period were enrolled. The comparison groups were enrolled in the same fashion. Interviewers completed a standardised intake form that was used by both centres and the following information was collected whenever possible: the patients self-assessment of the severity of NVP, which was measured by the Pregnancy-Unique Quantification of Emesis and Nausea (PUQE) scoring system recently created and validated by our team, where symptoms (nausea, vomiting and retching) are scored separately as reported by the women in the last 12 hours prior to their call,¹⁴ and any concurrent anti-emetic or other medication. Two other groups of women were enrolled concurrently: group 2, who also suffered from NVP but were not exposed to ondansetron, they had used other anti-emetics, which included Diclectin, metoclopramide, phenothiazines and ginger, and group 3, composed of women exposed to other drugs considered safe to use in pregnancy or those who had not used any medication.

The women were contacted 4–6 months after delivery to obtain outcome data using a standardised follow up form. Subsequent to the completion of the pregnancy follow up, the interviewer sent a letter to the caller's physician asking

for verification of the information obtained from the mother concerning the baby's health. We compared basic characteristics of the women, which included age, smoking and alcohol status and gestational age at time of call. The three groups were analysed to determine rates of live births, miscarriages, therapeutic abortions, stillbirths, major malformations, gestational age at birth and mean birthweights.

Outcome endpoints of interest between the study and the comparison groups were compared using χ^2 , Fishers exact and ANOVA statistical tests whenever appropriate. We obtained oral consent from each participant after the study was fully explained over the telephone and received ethics approval from our hospital's Research Ethics Board.

RESULTS

We were able to ascertain the outcomes of 176 women exposed to ondansetron who were all in the first trimester, most of whom were between 5 and 9 weeks of gestation and were using this drug for the treatment of NVP. All of the women in all three groups who were asked, agreed to participate and we enrolled 188 in the ondansetron group. We were, however, unable to complete follow ups on 12 of the women because of the inability to contact them. There were no significant differences in the maternal characteristics between the exposed and comparison groups, their ages were similar and very few smoked cigarettes or drank alcohol during pregnancy (Table 1). In the ondansetron group, there were 169 live births, 5 miscarriages, the mean gestational age was 38.7 weeks [1.7] and the mean birthweight was 3362 [525] g. There were six major malformations: three cases of hypospadias, double urinary collecting system in kidney, mild pulmonary stenosis and a duodenal atresia. After the study was completed, a physician phoned to inform us (January 2004) that a patient of his, who was in our study and gave birth to a normal child, had a second child also exposed to ondansetron, born with a mild hydronephrosis.

In the comparison group (1), there were three major malformations, hydrocephalus, kidney anomaly and aortic stenosis, and in the comparison group (2), there were also three malformations, one case of hypospadias and two congenital heart defects. There were no statistically significant differences between the three groups in terms of live births, miscarriages, stillbirths, therapeutic abortions, birthweight or gestational age. (Table 2) The rate of hypospadias (3/169) live births in the ondansetron group was not statistically

Table 1. Maternal characteristics of the women ($n = 176$ in each group). Values are given as mean (SD) or n (%).

Outcome	Ondansetron	Other anti-emetics	Non-tenipgen
Age	32.3 [4.4]	31.5 [4.3]	31.7 [4.4]
Smoking status	1 (0.5)	5 (2.8)	15 (8.5)
Alcohol use	2 (1.1)	1 (0.5)	3 (1.7)

Table 2. Comparison of pregnancy outcome among women exposed to ondansetron, other anti-emetic medications and non-teratogen drugs ($n = 176$ in each group). Values are given as mean (SD) or n (%).

Outcome	Ondansetron	Other anti-emetics	Non-teratogen	P
Live birth	169 (96.8)	160 (91)	162 (92)	0.68
Miscarriage	5 (2.9)	13 (7.5)	14 (8)	0.96
Stillbirth	0 (0)	1 (0.5)	0 (0)	0.70
Therapeutic abortion	2 (1.3)	2 (0.5)	0 (0)	0.89
Major malformation	6 (3.5)	3 (1.8)	3 (1.8)	0.52
Birthweight (grams)	3362 [525]	3372 [608]	3490 [666]	0.08
Gestational age at birth	38.7 [1.7]	38.7 [1.9]	39.4 [1.6]	0.57

significant from the combined controls (1/322, $P = 0.25$), however this sample size had only a 20% power to show the observed sixfold difference.

DISCUSSION

To our knowledge, this is the first study that examined the use of ondansetron in terms of safety during pregnancy. We were able to ascertain the outcomes of 176 pregnancies of women, all of whom were exposed during the first trimester of pregnancy in the period of organogenesis.

There were no statistical differences in the maternal characteristics of the women in the three groups and there were no statistical differences in any of the outcomes we examined. However, in the ondansetron group, there were three cases of hypospadias, which fit our criteria for major malformation because they required surgery. This is an increase in the rate of hypospadias in the general population (though not statistically significant), where this abnormality occurs in approximately 1 in every 300 males.¹⁵ Of note however, none of these hypospadias were categorized as severe, two of the three were described by the child's attending physician in the report as minor and one was described as moderate. Our sample size lacked power to show this apparent sixfold increase in this anomaly, thus, was not statistically significant. This increase in the rates of hypospadias was not shown in animal studies.¹⁰ More studies are required to achieve significant power to address any potential association between ondansetron and hypospadias.

Another interesting finding was the low rate (2.9%) of miscarriages in the ondansetron group compared with 7.5% and 8% in the comparison groups. This rate is considerably lower than is currently quoted in the literature, where many reports rely on approximate rates, rather than epidemiologic surveys. However, a recent study in Denmark did quote a 13% reported rate found in a surveillance study, which is twice as high as both of our comparison groups.¹⁶ This low rate of miscarriages found in our study may confirm that NVP does have a protective effect in pregnancy, which we also found in our most recent study examining the safety of

ginger for NVP in pregnancy, where there was an even lower rate of 1.6% in the women with NVP who had used ginger.¹⁷ The finding of a protective effect of NVP has also been reported in other studies of NVP.¹⁸ The confounding factor of this result however is that the rates of miscarriages in the second comparison group, which was comprised of other women with NVP who used other antiemetics. These were comparable with the third group of women who took other non-teratogen drugs or were not exposed to any drug, who also had relatively low rates compared with baseline. If NVP truly does have a protective effect, the rates of miscarriages in this group should have been similar to the ondansetron group rather than the non-teratogen group and there is no plausible explanation for this result.

A limitation of this study is the sample size, in which it has an 80% power to detect only a 3.5-fold increase in the rate of major malformations, with α of 0.05. Approximately 800 cases in each group would be required to detect a twofold risk of relatively common malformations and thousands of cases would be required to detect rare defects.

In summary, in our prospective cohort of 176 women who took ondansetron, all during the first trimester of pregnancy, there does not appear to be an increase in the rates of major malformations above the baseline. However, this is a small sample size and many more cases would be required to make a definitive conclusion. Nausea and vomiting can be a very debilitating and often ignored condition of pregnancy and this evidence-based information can be helpful to women and their health professionals when making a decision regarding treatment.

Acknowledgements

The Motherisk NVP Helpline is supported by Duchesnay, Laval, Quebec, Canada. The study was supported by an unrestricted grant from GlaxoSmithKline, Mississauga, Canada.

References

- Koren G, Bishai R. *Nausea and Vomiting of Pregnancy: State of the Art 2000*. Toronto: Motherisk, 2000.
- Godsby R, Bomic-Adshand AM, Ligger C. A prospective study of nausea and vomiting during pregnancy. *Br J Gen Pract* 1993;**43**(371): 245–248 (June).
- Levichek Z, Atanackovic G, Oepkes D, et al. Nausea and vomiting of pregnancy. Evidence-based treatment algorithm. *Can Fam Physician* 2002;**48**:267–268, 277 (February).
- Einarson T, Leader S, Koren G. A method for meta-analysis of epidemiological studies. *Drug Intell Clin Pharm* 1988;**22**:813–22824.
- Seto A, Einarson T, Koren G. Pregnancy outcome following first trimester exposure to antihistamines: meta-analysis. *Am J Perinatal* 1997;**14**(3):119–124 (March).
- Nageotte MP, Briggs GC, Towers CV, Asant T. Droperidol and diphenhydramine in the management of hyperemesis gravidarum. *Am J Obstet Gynecol* 1996;**174**:1801–1806.

THE SAFETY OF ONDANSETRON FOR NAUSEA AND VOMITING OF PREGNANCY 943

7. Halliher T, Bonn H, Georgousis A, Smith M, Einarsen A. The use of CAM by women suffering from nausea and vomiting during pregnancy. *BMC Complementary Altern Med* 2002;2(1):5 (May 17).
8. Berkovitch M, Mazzota P, Greenberg R, et al. Metoclopramide for nausea and vomiting of pregnancy: a prospective multicenter international study. *Am J Perinatol* 2002;19(6):311–316 (August).
9. Vutyavanich T, Kraissarin T, Ruangsri R. Ginger for nausea and vomiting in pregnancy: randomized, double-masked, placebo-controlled trial. *Obstet Gynecol* 2001;97(4):577–582 (April).
10. Tucker ML, Jackson MR, Scales MD, Spurling NW, Tweats DJ, Capel-Edwards K. Ondansetron: pre-clinical safety evaluation. *Eur J Cancer Clin Oncol* 1989;25(Suppl 1):S79.
11. Chowla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. *Cancer* 2003;97(9):2290–2300 (May 1).
12. Tinicello DG, Johnstone MJ. Treatment of hyperemesis gravidarum with the 5-HT3 antagonist ondansetron (Zofran). *Postgrad Med J* 1996;72(853):688–689 (November).
13. Sullivan CA, Johnson CA, Roach H, Martin RW, Stewart DK, Morrison JC. A pilot study of intravenous ondansetron for hyperemesis gravidarum. *Am J Obstet Gynecol* 1996;174(5):1565–1568 (May).
14. Koren G, Boskovic R, Hard M, Maltepe C, Navin Y, Einarsen A. Motherisk-PUQE (Pregnancy-Unique Quantification of Emesis and Nausea) scoring system for nausea and vomiting of pregnancy. *Am J Obstet Gynecol* 2002;186:S228–S231.
15. Rudolph CD. *Rudolph's Pediatrics, 21st edition*. New York: McGraw-Hill, 2003.
16. Rasch V. Cigarette, alcohol and caffeine consumption: risk factor for spontaneous abortion. *Acta Obstet Gynecol Scand* 2003;82:182–188.
17. Poetri G, Chng L, Karimi-Tabesh L, Koren G, Tan M, Einarsen A. A prospective comparative study of the safety and effectiveness of ginger for the treatment of nausea and vomiting in pregnancy (NVP). *Am J Obstet Gynecol* 2003;189(5):1374–1377 (November).
18. Zhou Q, O'Brien B, Relyea J. Severity of nausea and vomiting during pregnancy: what does it predict? *Birth* 1999;26(2):108–114 (June).

Accepted 15 March 2004